Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026
Tonix Pharmaceuticals announced a poster presentation at ISPOR 2026 featuring a retrospective analysis of U.S. real-world claims data on fibromyalgia patients. This follows the August 2025 FDA approval and November 2025 U.S. commercial launch of TONMYA® (cyclobenzaprine HCl sublingual tablets), the first new fibromyalgia treatment in over 15 years.…